Venture investors have historically favored early-stage deals, at least in medtech investing, willingly embracing greater technology or market risk for the larger returns that come with being first into a company. But as the challenges surrounding medtech have grown – challenges such as longer regulatory times, greater payor resistance, and uncertainty around present and future financing – fewer and fewer investors with appetites for early-stage deals remain. Many are moving to later-stage deals, where returns are lower, but come more quickly and with greater certainty; some are leaving medtech investing altogether.
The lack of early-stage investors has some worried: where will the next generation of late-stage deals come from if no...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?